Document:

EX-10.19

 Exhibit 10.19 
  

 
 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 Agreement on
addition of Additional Collaboration Program 
 hereinafter (“AACP”) 

made effective as of September 16th 2013 (“AACP Effective Date”). 

Addition of Additional Collaboration Program to the Research Plan, an integral part of the RESEARCH COLLABORATION AND LICENSE AGREEMENT dated
as of June 16, 2012 (the “Collaboration Agreement”) by and between 
  

	(1)	ZEALAND PHARMA A/S, a corporation organized and existing under the law of Denmark and having its registered office at Smedeland 36, DK-2600 Glostrup, Denmark (“Zealand”); and 

 

	(2)	PROTAGONIST PTY. LTD., a company organized and existing under the laws of Australia and having its registered office at 306 Carmody Road, St Lucia, Brisbane Qld 4072, Australia (“Protagonist Pty.
Ltd.”); and 

  

	(3)	PROTAGONIST THERAPEUTICS, INC., a Delaware corporation having its principal place of business 1455 Adams Drive, Suite 2003, Menlo Park, CA 94025 (“Protagonist Therapeutics” and together with Protagonist
Pty. Ltd., collectively, “Protagonist,”) 

 (Collectively the “Parties” and each a “Party”).

 WHEREAS, the Collaboration Agreement governs the collaboration between Zealand and Protagonist in the field of identifying and
characterize DRPs that bind to and have activity on a target selected by Zealand and approved by Protagonist in order that Zealand can further develop such DRPs to become or to be used in the development of therapeutics for the treatment of human
and animal diseases. 
 WHEREAS, the Parties have the option of modifying the Research Plan as to include additional services related
to the existing work on [*] of the Zealand Target. 
 NOW, THEREFORE, in consideration of the foregoing premises and the mutual
covenants herein contained, the Parties agree to: 
 Work together to agree on the [*] Research Plan and Research Modifications within sixty (60) days
from this AACP Effective Date as described in Section 2 below. 
 Terms of the Collaboration Agreement as follows: 

 

	1.	Capitalized Terms. Unless otherwise defined herein, any capitalized terms used in this AACP shall have the meanings ascribed to them in the Collaboration Agreement. 

 

	2.	 Additional Collaboration Program. In accordance with the terms laid out in Section 2.5 of the
Collaboration Agreement and by signing this AACP the Parties have agreed to add an Additional Collaboration Program (“Additional Collaboration Program no. 1”) to the Research Plan. Further, in accordance with Section 2.5 of the
Collaboration Agreement, the Parties have agreed to amend the Research Plan to include the Additional Collaboration Program no. 1. Such amendment shall include 

  
 1 

 

 
  

	 	Research Modifications as laid down in Section 2.5 of the Collaboration Agreement and be jointly drafted by the Parties. The amended Research Plan shall be adopted and executed by the Parties no later than sixty
(60) days from the AACP Effective Date unless mutually agreed to extend in writing, and will upon execution become an integral part of the Collaboration Agreement. For the avoidance of doubt, during such sixty (60) day period, Protagonist
shall not have any obligations to perform any work relating to the Research Plan. 

 Notwithstanding anything to the contrary in this AACP or
the Collaboration Agreement: 
  

	 	(i)	either Party may terminate the Additional Collaboration Program no. 1 and this AACP by providing written notice to the other Party no later than November 15 central European time, 2014 and 

 

	 	(ii)	upon such termination, neither Party shall have any further obligations under this AACP, to execute Additional Collaboration Program no. 1. 

 

	3.	No other Amendment. Save as specifically amended by this AACP the Collaboration Agreement shall continue in full force and effect in all respects. 

 

	4.	Counterparts. This AACP may be executed in any number of counterparts, each of which, when executed, shall be deemed an original and all of which together shall constitute one and the same instrument. Signatures
provided by facsimile transmission or in AdobeTM Portable Document Format (PDF) sent by electronic mail shall be deemed to be original signatures. 

IN WITNESS WHEREOF, the Parties have signed this AACP as of the Effective Date. 

 

			
	ZEALAND HARMA A/S
		
	By:	 	/s/ Arvind M. Hundal
	Arvind M. Hundal PhD
	Senior VP, CBO

  

			
	PROTAGONIST PTY. LTD
		
	By:	 	/s/ Dinesh V. Patel
	Name:	 	Dinesh V. Patel
	Title:	 	President & CEO

  

			
	PROTAGONIST THERAPEUTICS
		
	By:	 	/s/ Dinesh V. Patel
	Name:	 	Dinesh V. Patel
	Title:	 	President & CEO

  
 2 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.EX-10.20

 Exhibit 10.20 
  

			
	

	  	 Protagonist Therapeutics Inc

 
 521 Cottonwood Drive, Suite A

Milipitas CA 95035
 United States of
America
  
 Tel + 1 650 587 5766

 
 Protagonist Pty Ltd

ABN 44 098 201 944
  

PO Box 6421
 St Lucia Qld 4067

Australia
  

Tel + 61 7 3346 2975
 Fax + 61 7 3346
2379
  
 info@protagonist-inc.com

www.protagonist-inc.com

	 January 28, 2014
  

Arvind Hundal
 Zealand Pharma A/S

Smedeland 36
 DK-2600 Glostrup

Denmark
	  

 Dear Ms. Hundal, 
 It has
been our pleasure to work with Zealand Pharma A/S (“Zealand”) the last few years to identify and characterize potential new therapeutics using our Disulphide Rich Peptide (DRP) platform pursuant to the Research Collaboration
and License Agreement by and among Zealand, Protagonist Therapeutics, Inc. (“Protagonist”) and our wholly owned subsidiary, Protagonist Therapeutics, Inc. (together with Protagonist, the “Company,”
“us,” or “we”), dated June 16, 2012, as amended and extended from time to time (the “Agreement”), whereby we laid out the terms and conditions of our collaboration. All
capitalized terms used herein that are not defined herein will have the meanings ascribed thereto in the Agreement. 
 As you know, we received a written
notification of Abandonment from you on October 30, 2013 pursuant to Section 13.1 of the Agreement informing us that Zealand wished to Abandon the Collaboration Program, including the development and/or commercialization of all specific
Selected DRPs and Therapeutic Peptides or Products in the Collaboration Program. 
 The purpose of this letter is to notify you in accordance with
Section 13.4 of the Agreement that we wish to modify the Agreement in order to assume responsibility for the development and/or commercialization of all of the Selected DRPs, Therapeutic Peptides and Products in the Collaboration Program. 

We place great value in the relationship we have established with Zealand over the past few years and wish you great success in your future development and
commercial endeavors. 
 Please indicate Zealand’s acknowledgement that we have provided you with proper notice under the Agreement of our intention to
modify the Agreement in order to assume responsibility of the Collaboration Program by signing below where indicated. 

Best Regards, 

/s/ Dinesh V. Patel 

Dinesh V. Patel, Ph.D. 

President and CEO 

Acknowledged and Agreed: 
  

	
	ZEALAND PHARMA A/S
	
	/s/ Arvind M. Hundal 30-1/2014
	Arvind M. Hundal, Ph.D.
	Senior Vice President and CBOEX-10.21

 Exhibit 10.21 
  

 
 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 AGREEMENT TO
ASSIGN PATENT APPLICATIONS 
 THIS AGREEMENT (this “Agreement”) is entered into as of February 7th, 2014 (“Effective Date”) by 

 

	(1)	ZEALAND PHARMA A/S, a corporation organized and existing under the law of Denmark and having its registered office at Smedeland 36, DK-2600 Glostrup, Denmark (“Zealand”); and 

 

	(2)	PROTAGONIST PTY. LTD., a company organized and existing under the laws of Australia and having its registered office at 306 Carmody Road, St Lucia, Brisbane Qld 4072, Australia (“Protagonist Pty. Ltd.”)
; and 

  

	(3)	PROTAGONIST THERAPEUTICS, INC., a Delaware corporation having its principal place of business 521 Cottonwood Dr., Suite A, Milipitas, Ca95035-7404 (“Protagonist Therapeutics” and together with
Protagonist Pty. Ltd., collectively, “Protagonist”) 

  

	    	(Collectively the “Parties” and each a “Party”). 

 WHEREAS, the Parties have entered
into a RESEARCH COLLABORATION AND LICENSE AGREEMENT dated as of June 16, 2012 as amended by Agreement on addition of Additional Collaboration Program, dated 16th September 2013
(“Collaboration Agreement”); 
 WHEREAS, Zealand has on 30th October 2013 sent a formal notice to Protagonist of its decision to
Abandon the Collaboration Program; 
 WHEREAS, upon Abandonment of a Collaboration Program, Zealand Research IP and Option Research IP owned
by Zealand, used exclusively with respect to such Collaboration Program, automatically is deemed assigned to Protagonist and Zealand agrees to take such steps as may reasonably requested by Protagonist, and at the sole expense of Protagonist, in
order to complete this assignment. 
 NOW, therefore, and in consideration of the mutual covenants contained herein, and for other good and
valuable consideration receipt of which each party hereby acknowledges, the parties hereby agree as follows: 
 Unless otherwise defined herein, any
capitalized terms used in this Agreement shall have the meanings ascribed to them in the Collaboration Agreement. 
 1. DEFINITIONS 

1.1 “Assigned Patent Applications” shall mean the patent applications listed in Exhibit 1, and all Intellectual Property Rights therein and thereto.

  
 [*] = Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 

 
  
 1.2 “Intellectual Property Rights” shall
mean copyrights, patents (including patent improvements), patent applications, trade secrets or other intellectual property rights (but not trademarks, trade names or service marks) under applicable law used exclusively with respect to a
Collaboration Program. 
 2. ASSIGNMENT. 
 2.1 Zealand
hereby assigns all right, title and interest in and to the Assigned Patent Applications. In order to effect such ownership transfer, contemporaneously with the execution of this Agreement, Zealand has executed that certain separate assignment
document, to be recorded with the United States Patent and Trademark Office. Zealand shall reasonably cooperate with Protagonist in the filing and prosecution of the Assigned Patent Applications. 

2.2 Without undue delay, Zealand shall deliver to Protagonist all relevant documentation pertaining to the Assigned Patent Applications, including copies of
all correspondence to or from examining authorities regarding such Assigned Patent Applications, patents and prior art searches pertaining to such Assigned Patent Applications, and all correspondence with any attorney involved in the preparation
and/or prosecution of the Assigned Patent Applications. 
 2.3 Zealand hereby assigns to Protagonist all Zealand Research IP and Option Research IP that
were used exclusively with respect to Collaboration Programs. 
 3. TRANSFER COST 

3.1 Protagonist promptly shall reimburse any and all expenses paid by Zealand to complete this assignment and Zealand will forward an invoice on the amount of
[*] to this effect. The invoice shall contain the specific terms of payment. 
 4. WARRANTIES AND LIMITATION OF LIABILITY 

4.1 WARRANTIES. 
 4.1.1 Zealand represents and warrants that:
(a) it is a corporation duly organized, validly existing, and in good standing under the laws of the State of New York and has full power and authority to enter into this Agreement and perform its obligations hereunder; (b) immediately
prior to the execution of this Agreement, Zealand owns all right, title and interest in and to the Assigned Patent Applications; and (c) it has the legal right to grant all the rights it purports to grant and to convey all the rights it intends
to convey pursuant to Section 2.1 above. 
 4.1.2 Protagonist represents and warrants that: it is a corporation duly organized, validly existing, and
in good standing under the laws of the State of New York and has full power and authority to enter into this Agreement and perform its obligations hereunder. 

4.1.3 EXCEPT AS PROVIDED IN THIS SECTION 4.1, EACH PARTY DISCLAIMS ALL WARRANTIES, EITHER EXPRESS, IMPLIED OR STATUTORY, INCLUDING BUT NOT LIMITED TO ANY (IF
ANY) IMPLIED WARRANTIES OF MERCHANTABILITY, OF FITNESS FOR A PARTICULAR PURPOSE, AND OF LACK OF NEGLIGENCE OR LACK OF WORKMANLIKE CONDUCT OR EFFORT. ALL PATENT APPLICATIONS ASSIGNED UNDER THIS AGREEMENT ARE PROVIDED AS IS WITH ALL FAULTS, AND NO
WARRANTIES OR PROMISES 

  
 2 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 

 
  
 ARE MADE THAT THE SAME WILL WORK OR WORK FOR ANY
PARTICULAR PURPOSE. EXCEPT AS PROVIDED IN THIS SECTION 4.1, THERE IS NO WARRANTY OF TITLE, AUTHORITY OR NON-INFRINGEMENT IN ANY SUCH PATENT APPLICATIONS. 

4.2 LIMITATION OF LIABILITY. TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, IN NO EVENT SHALL ANY PARTY BE LIABLE FOR ANY SPECIAL, INCIDENTAL OR
CONSEQUENTIAL DAMAGES WHATSOEVER ARISING OUT OF OR IN ANY WAY RELATED TO THIS AGREEMENT, EVEN IF THE PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. THE IMMEDIATELY PRECEDING SENTENCE SHALL HAVE NO APPLICABILITY TO ANY LEGAL CAUSE OF
ACTION ARISING FROM ANY PARTY’S ACTIVITIES OUTSIDE THE SCOPE OF THIS AGREEMENT. 
 5. GENERAL 

5.1 ENTIRE AGREEMENT. This Agreement is intended to execute the assignment of Zealand Research IP and Option Research IP owned by Zealand used exclusively with
respect to a Collaboration Program and the Parties acknowledge that applicable obligations and rights laid out in the Collaboration Agreement shall continue in force. In the event of any conflicts between terms of this Agreement and Collaboration
Agreement, the terms of this Agreement shall control. 
 5.2 AMENDMENT. This Agreement shall not be amended or otherwise modified except by a written
agreement dated subsequent to the date of this Agreement and signed on behalf of Zealand and Protagonist by their respective duly authorized representatives. 

5.3 GOVERNING LAW. This Agreement shall be governed by, construed and enforced in accordance with the laws of the State of New York, United States of America
without giving regard to its conflict of law rules. 
 5.4 ASSIGNMENT. This Agreement shall be binding upon and inure to the benefit of the parties hereto
and their respective successors and assigns. 
 5.5 NO WAIVER. No waiver of any breach of any provision of this Agreement shall constitute a waiver of any
prior, concurrent or subsequent breach of the same or any other provisions hereof, and no waiver shall be effective unless made in writing and signed by an authorized representative of the waiving party. 

5.6 SAVINGS CLAUSE. If any provision of this Agreement shall be held by a court of competent jurisdiction to be illegal, invalid or unenforceable, the
remaining provisions shall remain in full force and effect. 
 5.7 FURTHER ASSURANCES. Each party agrees to take such further action and execute, deliver
and/or file such documents or instruments as are necessary to carry out the terms and purposes of this Agreement. 
 5.8 SECTION HEADINGS. The section
headings used in this Agreement are intended for convenience only and shall not be deemed to supersede or modify any provisions. 

  
 3 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 

 
  
 IN WITNESS WHEREOF, the parties have executed this
Agreement as of the Effective Date. 
  

			
	ZEALAND PHARMA A/S
		
	By:	 	/s/ Arvind M. Hundal
		
	Name:	 	Arvind M. Hundal, PhD
		
	Title:	 	Senior Vice President CBO
		
	Date:	 	2nd May 2014
	
	PROTAGONIST PTY. LTD
		
	By:	 	/s/ Dinesh V. Patel
		
	Name:	 	Dinesh V. Patel
		
	Title:	 	President & CEO
		
	Date:	 	5-12-2014
	
	PROTAGONIST THERAPEUTICS, INC.
		
	By:	 	/s/ Dinesh V. Patel
		
	Name:	 	Dinesh V. Patel
		
	Title:	 	President & CEO
		
	Date:	 	5-12-2014

  
 [*] = Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 

 
  
 Exhibit 1: ASSIGNED PATENT
APPLICATIONS 
  

													
	 Reference
	  	 Country
	  	Official Title	  	Application
No	  	Filing Date	  	Case Status	  	Case Type
							
	 [*]
	  	[*]	  	[*]	  	[*]	  	[*]	  	[*]	  	[*]
							
	 [*]
	  	[*]	  	[*]	  	[*]	  	[*]	  	[*]	  	[*]

  
 [*] = Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00260-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00260-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00260-of-00352.parquet"}]]